REGENXBIO to Participate in Upcoming Investor Conferences
Igår, 22:05
Igår, 22:05
REGENXBIO to Participate in Upcoming Investor Conferences
PR Newswire
ROCKVILLE, Md., May 18, 2026
ROCKVILLE, Md. , May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
2026 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 20 at 9:30am ET
Location: New York, NY
Stifel 2026 Virtual Ophthalmology Forum
Fireside Chat: Tuesday, May 26 at 9:30am ET
Location: Virtual
Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com . Archived replays of the webcasts will be available for approximately 30 days following the events.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM .
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

SOURCE REGENXBIO Inc.

Igår, 22:05
REGENXBIO to Participate in Upcoming Investor Conferences
PR Newswire
ROCKVILLE, Md., May 18, 2026
ROCKVILLE, Md. , May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
2026 RBC Capital Markets Global Healthcare Conference
Fireside Chat: Wednesday, May 20 at 9:30am ET
Location: New York, NY
Stifel 2026 Virtual Ophthalmology Forum
Fireside Chat: Tuesday, May 26 at 9:30am ET
Location: Virtual
Live webcasts of select events can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com . Archived replays of the webcasts will be available for approximately 30 days following the events.
ABOUT REGENXBIO Inc.
REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases, including RGX-202 for the treatment of Duchenne; clemidsogene lanparvovec (RGX-121) for the treatment of MPS II and RGX-111 for the treatment of MPS I, both in partnership with Nippon Shinyaku; and surabgene lomparvovec (ABBV-RGX-314) for the treatment of wet AMD and diabetic retinopathy, in collaboration with AbbVie. Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Novartis' ZOLGENSMA®. REGENXBIO's investigational gene therapies have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM .
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
George E. MacDougall
Investor Relations
IR@regenxbio.com

SOURCE REGENXBIO Inc.

Analys
Analys
1 DAG %
Senast
OMX Stockholm 30
0,63%
(17:30)
Shein
Igår, 15:24
Shein slukar ESG-profilerade Everlane
OMX Stockholm 30
1 DAG %
Senast
3 055,52